Bailey Pemberton
4 min read
-
Leidos Holdings reported Q3 2026 sales of US$4,630 million and net income of US$410 million, raised full year adjusted earnings guidance, completed a US$504 million buyback of 3,808,570 shares, and declared a quarterly dividend of US$0.45 per share.
-
Management paired higher profitability and guidance with active capital returns through buybacks and dividends, while also securing new long term defense and cyber contracts that shape Leidos Holdings’ future workload mix.
-
This article examines how Leidos Holdings’ stronger earnings guidance and profitability may influence the investment narrative around its defense technology strategy.
Scan how Leidos Holdings’ buybacks, dividend moves and defense contracts compare with other contractors returning cash while leaning into long-term programs through our curated 41 power grid technology and infrastructure stocks
Leidos Holdings Investment Narrative Recap
To hold Leidos Holdings, you need to be comfortable with a contractor leaning heavily on U.S. government work while trying to grow higher margin defense tech and cyber programs. The latest quarter showed higher earnings and EPS despite slightly softer revenue, and management trimmed 2026 sales guidance while still lifting adjusted EPS expectations.
In the near term, the key swing factor is execution on funded defense tech and cyber awards, especially as Defense margins and Health contract terms come under pressure. The main risk sits with budget or contract changes and Health profitability, so the lowered revenue outlook looks relevant rather than noise for anyone focused on near term momentum.
The most important recent announcement for this story is the missile industrial base effort tied to the Low Cost Containerized Missile and AGM 190A Havoc Spear programs. A framework for 3,000 LCCM weapons and current Havoc Spear deliveries give Leidos Holdings tangible hardware production work that complements its software and services footprint.
These missile programs connect directly to the catalysts around expanding higher margin defense technology and munitions. They also increase exposure to U.S. defense funding priorities and execution risk around scaling production at Huntsville, McEwen and a broad supplier base. For shareholders, the question is whether operational delivery on these awards can offset Health headwinds and slightly lower revenue guidance.
Leidos Holdings’ current analyst narrative points to about US$20.0b in revenue and US$1.5b in earnings by 2029, built on forecast revenue growth of 4.4% a year and an earnings move from US$1.4b today to US$1.5b, which is an increase of roughly US$0.1b.
